Bateman ED, Guerreros AG, Brockhaus F, et al. Fevipiprant, an oral prostaglandin DP₂ receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. Eur Respir J. 2017;50.
CINQAIR® (reslizumab) [prescribing information]. Frazer, PA: Teva Respiratory, LLC; Approved 2016. Revised January 2019.
ClinicalTrials.gov. Study to evaluate tezepelumab in adults & adolescents with severe uncontrolled asthma (NAVIGATOR). https://clinicaltrials.gov/ct2/show/NCT03347279. Accessed July 15, 2019.
ClinicalTrials.gov. Study to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma (SOURCE). https://clinicaltrials.gov/ct2/show/NCT03406078. Accessed July 15, 2019.
ClinicalTrials.gov. Study of efficacy and safety of QAW039 in patients with severe asthma inadequately controlled with standard of care asthma treatment. https://clinicaltrials.gov/ct2/show/NCT02563067. Accessed July 15, 2019.
Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377:936-946.
DUPIXENT® (dupilumab) [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; Approved 2017. Revised June 2019.
FASENRA™ (benralizumab) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; Approved 2017. Revised November 2017.
Hambly N, Nair P. Monoclonal antibodies for the treatment of refractory asthma. Curr Opin Pulm Med. 2014;20:87-94.
Keller M, Kamp D. Severe asthma: the evolution of patient-directed management. Clin Pulm Med. 2014;21:1-8.
Krings JG, McGregor MC, Bacharier LB, et al. Biologics for severe asthma: treatment-specific effects are important in choosing a specific agent. J Allergy Clin Immunol Pract. 2019;7:1379-1392.
Manka LA, Wechsler ME. Selecting the right biologic for your patients with severe asthma. Ann Allergy Asthma Immunol. 2018;121:406-413.
Maselli DJ, Rogers L, Peters JI. Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use. Ther Clin Risk Manag. 2018;14:2059-2068.
McGregor MC, Krings JG, Nair P, et al. Role of biologics in asthma. Am J Respir Crit Care Med. 2019;199:433-445.
NUCALA (mepolizumab) [prescribing information]. Philadelphia, PA: GlaxoSmithKline LLC; Approved 2015. Revised June 2019.
XOLAIR® (omalizumab) [prescribing information]. South San Francisco, CA: Genentech, Inc; Approved 2003. Revised May 2019.

AAAAI Disclosure Policy

Pursuant to the Code of Ethics for the American Academy of Allergy, Asthma & Immunology (AAAAI) and the Standards for Commercial Support of Continuing Medical Education of the Accreditation Council for Continuing Medical Education, the AAAAI requires disclosure of certain information from faculty members of educational activities designated for CME credit by the AAAAI. Prior to the activity, authors and reviewers are required to disclose all relationships that meet the following parameters:

• Employment. Name of employer and job title.

• Financial interests. All organizations, other than the employer, from which the faculty member or a member of his/her immediate family or household receives annual remuneration in any amount (including grants, honoraria and consulting fees).

• Research interests. All organizations which support research projects for which the faculty member or member of his/her immediate family or household serves as an investigator.

• Legal Consultation Services/Expert Witness Testimony: All topics on which the faculty member provided legal consultation and/or expert witness testimony during the previous calendar year.

• Organizational interests: All organizations, other than the AAAAI, for which the faculty member holds volunteer positions.

• Gifts. All organizations from which the faculty member or a member of his/her immediate family or household have received a gift of any amount in the last year.

• Other interests. All interests of the faculty member or a member of his/her immediate family or household that would be judged by a majority of his/her peers to be more than casual and/or likely to impact his/her ability to exercise independent judgment. This includes any financial interest in or relationship with any manufacturer of a commercial product, and any financial interest or relationship with any organization that provides commercial support to AAAAI-sponsored educational activities.

The information disclosed by the speakers and planning committee was reviewed in accordance with the AAAAI Disclosure Policy. All potential conflicts of interest were resolved by the planners, faculty, and reviewers prior to their participation in the development of this activity.

Faculty

William Busse, MD

Professor of Medicine
Division of Allergy and Pulmonology and Critical Care Medicine
University of Wisconsin School of Medicine & Public Health
Madison, Wisconsin

Disclosures

Disclosure: William W. Busse, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; ResTORbio Inc.; Sanofi; TEVA PHARMACEUTICALS USA
Other: DSMB: Boston Scientific

Thomas B. Casale, MD

Professor of Internal Medicine
Division of Allergy and Immunology
Morsani College of Medicine
University of South Florida
Tampa, Florida

Disclosures

Disclosure: Thomas B. Casale, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Sanofi
Served as a speaker or a member of a speakers bureau for: Genentech, Inc.
Received grants for clinical research from: Genentech, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Sanofi

Editors

Roderick Smith, MS

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Roderick Smith, MS, has disclosed no relevant financial relationships.

Anita A. Galdieri, RPh, PharmD

Senior Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Anita A. Galdieri, RPh, PharmD, has disclosed no relevant financial relationships.

Content Reviewers

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Amy Bernard, MS, BSN, RN-BC, CHCP

Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

Kevin Parks, MD FAAAAI AAC/CRI of Southern Oregon, Medford, OR
Relevant relationships: None

CME

Foundations of Asthma: When to Consider Biologic Therapy

Authors: William W. Busse, MD; Thomas B. Casale, MD
CME Released: 9/23/2019
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 9/23/2020

Start Activity

Target Audience and Goal Statement

This activity is intended for allergists & clinical immunologists, pulmonologists, and primary care physicians.

The goal of this activity is to improve clinicians' knowledge regarding the mechanisms of action, dosing, and other characteristics of biologic agents for severe asthma in order to aid therapy selection for patients.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Pathophysiologic targets for biologic therapies in patients with asthma
- Role of allergists in managing patients with asthma using biologic therapies

Disclosures

AAAAI Disclosure Policy

• Employment. Name of employer and job title.

• Research interests. All organizations which support research projects for which the faculty member or member of his/her immediate family or household serves as an investigator.

• Legal Consultation Services/Expert Witness Testimony: All topics on which the faculty member provided legal consultation and/or expert witness testimony during the previous calendar year.

• Organizational interests: All organizations, other than the AAAAI, for which the faculty member holds volunteer positions.

• Gifts. All organizations from which the faculty member or a member of his/her immediate family or household have received a gift of any amount in the last year.

Faculty

William Busse, MD

Professor of Medicine
Division of Allergy and Pulmonology and Critical Care Medicine
University of Wisconsin School of Medicine & Public Health
Madison, Wisconsin

Disclosures

Disclosure: William W. Busse, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; ResTORbio Inc.; Sanofi; TEVA PHARMACEUTICALS USA
Other: DSMB: Boston Scientific

Thomas B. Casale, MD

Professor of Internal Medicine
Division of Allergy and Immunology
Morsani College of Medicine
University of South Florida
Tampa, Florida

Disclosures

Disclosure: Thomas B. Casale, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Sanofi
Served as a speaker or a member of a speakers bureau for: Genentech, Inc.
Received grants for clinical research from: Genentech, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Sanofi

Editors

Roderick Smith, MS

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Roderick Smith, MS, has disclosed no relevant financial relationships.

Anita A. Galdieri, RPh, PharmD

Senior Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Anita A. Galdieri, RPh, PharmD, has disclosed no relevant financial relationships.

Content Reviewers

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Amy Bernard, MS, BSN, RN-BC, CHCP

Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

Kevin Parks, MD FAAAAI AAC/CRI of Southern Oregon, Medford, OR
Relevant relationships: None

Accreditation Statements

For Physicians

The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AAAAI is accredited by the ACCME to provide continuing medical education for physicians.

AAAAI Privacy Policy

The American Academy of Allergy, Asthma & Immunology designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

To verify your participation in educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at [email protected]

Contact this provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Allergy & Clinical Immunology

CME

Foundations of Asthma: When to Consider Biologic Therapy

Authors: William W. Busse, MD; Thomas B. Casale, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 9/23/2019

Valid for credit through: 9/23/2020

processing....

Abbreviations

CRS = chronic rhinosinusitis
DP₂ = prostaglandin D₂
FARE = Food Allergy Research & Education
FcεRI = high-affinity IgE receptor
FEV₁ = forced expiratory volume in one second
ICS = inhaled corticosteroid
IgE = immunoglobulin E
IL = interleukin
IL-4Rα = IL-4 receptor alpha
IL-5Rα = IL-5 receptor alpha
IL-13Rα = IL-13 receptor alpha
IV = intravenous
mAb = monoclonal antibody
MOA = mechanism of action
OCS = oral corticosteroid
SC = subcutaneous
T2 = type 2 cell endotype
TGF = transforming growth factor
Th = T helper
TSLP = thymic stromal lymphopoietin
yo = years old